AstraZeneca (LSE: AZN) is expected to report Q3 earnings on Oct. 26. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AstraZeneca's revenues will wither -17.6% and EPS will contract -15.8%.
The average estimate for revenue is $6.77 billion. On the bottom line, the average EPS estimate is $1.44.
Revenue details
Last quarter, AstraZeneca booked revenue of $6.66 billion. GAAP reported sales were 21% lower than the prior-year quarter's $8.43 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $1.53. GAAP EPS of $1.27 for Q2 were 17% lower than the prior-year quarter's $1.53 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 79.9%, 280 basis points worse than the prior-year quarter. Operating margin was 31.9%, 490 basis points worse than the prior-year quarter. Net margin was 24.2%, 90 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $28.28 billion. The average EPS estimate is $5.98.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 44 members out of 49 rating the stock outperform, and five members rating it underperform. Among one CAPS All-Star picks (recommendations by the highest-ranked CAPS members), one give AstraZeneca a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $46.69.
Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and get "The 3 DOW Stocks Dividend Investors Need." Click here for instant access to this free report.
- Add AstraZeneca to My Watchlist.
